Skylight Health Group (TSXV: SLHG) (NASDAQ: SLHG): Recent Episodes
Skylight Health Group
News and updates from Skylight Health Group, listed on the TSXV: SLHG and on the NASDAQ: SLHG. Skylight Health Group is a healthcare services and technology company, working to positively impact patient health outcomes. The Company operates a US multi-state primary care health network comprised of physical practices providing a range of services from primary care, sub-specialty, allied health, and laboratory/diagnostic testing.
Skylight Health Group (SLHG) CEO Prad Sekar Provides News Release Update - Sept 15, 2021
Skylight Health Group (NASDAQ: SLHG | TSXV: SLHG) Prad Sekar discusses the appointment of Mohammad Bataineh as President.
Prad Sekar CEO of Skylight Health Group (NASDAQ: SLHG) (TSXV: SLHG) Discusses the Concept of Value Based Care
After acquiring ACO Partners, CEO Prad Sekar provides some added context and gives a deeper understanding of how this positively impacts Skylight's mission to be a national leader in value-based care.
Prad Sekar, CEO of Skylight Health Group (NASDAQ: SLHG) (TSXV: SLHG) provides provides corporate update after Company's Annual General & Special Meeting.
Prad Sekar, CEO of Skylight Health Group (NASDAQ: SLHG) (TSXV: SLHG) provides a shareholder update for the June 24, 2021 news release announcing the acquisition of the Doctors Center in Jacksonville, FL
JOIN THE FIT FAM https://fitraders.com/join-fit/ https://fitraders.com/education/intro... Welcome to FIT!!! visit us at www.fitraders.com Live Stock Market analysis, focused on Technical analysis, Fundamental analysis and Trading Psychology. Follow us on instagram: www.instagram.com/FITraders Follow us on twitter: https://twitter.com/FiTradersRick EDUCATIONAL CONTENT DISCLAIMER
SKYLIGHT HEALTH TO ACQUIRE US CLINIC GROUP with over $20 million in Revenue - RICH TV LIVE - January 7, 2020 - SKYLIGHT HEALTH TO ACQUIRE US CLINIC GROUP WITH OVER 6 LOCATIONS, $20 MILLION IN REVENUE AND $3 MILLION EBITDA Skylight Health to acquire US-based Healthcare Group which operates a network of over 6 primary and urgent care centers. 2020 unaudited revenue of over $20 million and $3 million EBITDA. Immediately accretive deal strengthens organizational team with a robust, centralized corporate infrastructure for national network. Skylight Health forecasted annual revenue run rate now over $45 million and EBITDA run rate of $5.5 million after closing of the transaction. Transaction expected to close Q1 2021. Skylight Health Group Inc (TSXV:SHG; OTCQX: SHGFF) (“Skylight Health”, “SHG” or the “Company”), one of the largest multi-specialty healthcare systems in the United States, is pleased to announce that it has entered into a Binding Letter of Intent (LOI) (the “Transaction), signed on January 6, 2021 to purchase 100% of the shares of a US Primary and Urgent Care clinic group (the “Clinic”) in an arms-length acquisition. For confidentiality reasons, the name and location of the group will remain undisclosed until the closing of the Transaction before the end of Q1 2021. The planned acquisition of the Clinic expands the Company’s bricks and mortar and telemedicine services within one of the existing Skylight Health states. The Clinic has been operating an established and fast-growing network of primary care clinics. The group is actively credentialed with major insurance carriers. Aligned with SHG’s multi-disciplinary strategy, the Clinic employs a multi-disciplinary approach to patient care management. The Clinic has been successful in servicing Regional Health Systems with pre & post acute care, reducing emergency room visits and readmissions within the communities it serves. The Clinic’s clinical staff mix includes physicians, nurse practitioners, and physician assistants. The Clinic adds immediate incremental revenue to SHG as it strengthens its market share within an existing state, as well as builds upon the infrastructure to support SHG’s national network of clinics and further growth. The Clinic has built a sustainable and scalable corporate infrastructure including in-house revenue cycle management, credentialing, centralized scheduling, compliance, and medical leadership. SHG expects continuity of its leadership team and clinical staff post-acquisition. Prad Sekar, CEO, Skylight Health said, “This is an exciting acquisition for SHG. Not only does this further strengthen our position in the US market to bring a one-stop shop approach to care for patients, but significantly reinforces our corporate infrastructure to further scale across other US markets. We have highlighted several transactions of material size throughout 2020 and we are glad to begin executing against this pipeline. With each acquisition, we enhance and strengthen our team to continue to build value for patients and drive fundamental business growth.”
BREAKING NEWS: Skylight Health Group (CSE: SHG) (OTCQX: SHGFF) - December 10, 2020 - RICH TV LIVE - Florida based primary and urgent care clinic group is an established medical practice. In 2019, the clinic generated CAD 5 million in revenues and CAD 1.2 in EBITDA. Skylight Health’s forecasted annual run rate to now be over CAD 25 million combined with the completion of the previous five announced transactions. Total consideration value of CAD 4.8 million (50% cash, 50% shares) for the acquisition representing a 4x EBITDA multiple. This transaction will be immediately accretive to the Company adding experienced management, new complementary services and expansion of services to existing US markets.
Skylight Health Group Inc (CSE:SHG; OTCQX: SHGFF) (“SHG” or the “Company”), one of the largest multi-specialty healthcare systems in the United States, is pleased to announce that it has entered into a Letter of Intent (LOI) to purchase 100% of the shares of a Florida Primary and Urgent Care clinic group (the “Clinic”). The name of the group will remain undisclosed until the closing of the Transaction on or before January 31, 2021. The planned acquisition of the Clinic will expand the Company’s bricks and mortar and telemedicine services to 16 States when including the previously announced pending acquisition of Tennessee-based Perimeter Pain and Primary Care Clinic.
The Clinic has been operating an established and fast growing multi-disciplinary network of clinics representing 6 locations across Florida. Services to patients include primary care, urgent care, allied health & wellness, laboratory procedures, drive up COVID-19 testing, and preventive screenings among others. Services provided by the Clinic are primarily reimbursed through insurance carriers including Medicare, Medicaid and other commercial payors. The Clinic also leverages telemedicine as a delivery model for its existing patient base.
The Company expects to see continued growth in patient registrations and visits as the Clinic continues to thrive notwithstanding the challenges most clinics have faced due to the recent COVID-19 pandemic. Management will remain with the Company to continue to accelerate growth across the state of Florida. Further, management will leverage their knowledge of developing a working and robust multi-disciplinary practice of allied health offerings to expand services within existing SHG clinics across other US markets. This will immediately drive new service opportunities for the current Skylight Health national base of 120,000 patients and add new insurable services revenues organically.
Prad Sekar, CEO, Skylight Health said “This acquisition is a critical component in building our multi-disciplinary model by the addition of a proven management team to help SHG build out its robust national platform. The Clinic has been innovative in its approach to bridge wellness and traditional healthcare together. This aligns with SHG’s platform model and enables us to rapidly expand on services to the growing Florida market and simultaneously integrate these services across our other US markets improving the lives of our national roster of patients. Accretive acquisitions remain our number one focus and we are beyond excited to add the Clinic to our growing network of practices.”
Skylight Health Group CEO Prad Sekar (CSE: SHG) (OTCQX: CBIIF) - RICH TV LIVE - DECEMBER 3, 2020 - Skylight Health Group Inc (CSE:SHG; OTCQX: CBIIF) (“SHG” or the “Company”), one of the largest multi-specialty healthcare systems in the United States, is pleased to announce that it has entered into a Letter of Intent (LOI) to purchase the assets of Healthcare Resources Management LLC (“HRM”) which operates Perimeter Pain and Primary Clinic (“Perimeter”) in Cookeville, Tennessee. The planned acquisition of HRM expands the Company’s bricks and mortar and telemedicine services to 15 States and will add 12,000 new patients to its current roster of 120,000.
HRM has been operating Perimeter in Cookeville for over 7 years with strong patient retention. Services to patients include primary care, chronic pain management, interventional procedures, weight management, regenerative medicine and aesthetics. Services provided by Perimeter are primarily reimbursed through insurance carriers including Medicare, Medicaid and other commercial payors.
The Company expects to see continued growth in patient registrations and visits as Perimeter continues to thrive among the challenges most clinics have faced due to the recent COVID-19 pandemic. Further, the Company will work quickly to expand on the current offering of services by leveraging its current telemedicine infrastructure to provide access to patients across the state of Tennessee. Upon completion, services offered by Perimeter will apply to Skylight Health’s entire patient base. These services are immediately accretive as they allow the Company to expand complementary billable services. Patients will continue to benefit from the expansion of services in-house. The Company will benefit by expanding the per patient insurable revenue share-of-wallet by retaining these services internally.
“Perimeter represents the first of complementary non-primary care acquisitions and is in direct alignment with our strategy to expand on services offered to our existing patient base nationally,” said Prad Sekar, CEO, Skylight Health. “Adding vital services like chronic pain management, interventional procedures and other from Perimeter will benefit tens of thousands of our current patients and will be deployed nationally within the existing framework of payor contracts in each state we are organically establishing over the next year.”
HRM represents the fourth announced acquisition by the Company in the last 60 days. This acquisition supports and strengthens the 3-prong growth model which includes growth from the current infrastructure, new services and acquisitions.
The Company will pay as per the agreed upon terms of the LOI, a transaction value in cash of CAD 1.03 million representing an EBITDA multiple of 2.6x. Perimeter reported revenues in 2019 of CAD 2.2 million and net income of CAD 400,000. This transaction is subject to a satisfactory due diligence period by the Company and mutual agreement to an Asset Purchase Agreement and Closing Conditions. The transaction is expected to close on or before December 31, 2020. #skylighthealthgroup #telemedicine #richtvlive The Company also announces the grant of 3,176,000 options to the directors and senior officers. Options have been granted as of the close of business December 2, 2020 at a strike price of $0.77 with no discount. The Company has also issued 125,000 shares at a price of $0.62 to certain consultants for services delivered.
Prad Sekar CEO, CB2 Insights - Virtual Conference, Gravitas Technology and Diversified Day
CB2 Insights has launched the first in a series of monthly medical reports derived from real-world clinical treatments on a variety of healthcare conditions and modalities across the United States, Canada and United Kingdom.
CB2 Insights (CSE: CBII; OTCQB: CBIIF) CEO Prad Sekar joined Steve Darling from our Toronto studio to provide details the will begin a prospective trial with GL Brands that will assess the safety, efficacy and other health measures for patients using Green Lotus’ cannabidiol soft gel capsules when looking to treat anxiety. Sekar discusses how this trial will be carried out and what the data gained from it will be used for.
CB2 Insights Inc (CSE:CBII) (OTCQB:CBIIF) CEO Prad Sekar tells Proactive that the Ontario-based company is partnering with licensed producer FCM Global S.A.S. Sekar says FCM Global is one of the only fully licensed Colombian cannabis producers where CB2 will support its medical cannabis research and clinical trials. Sekar is in New York presenting at the Piper Jaffray Healthcare Conference.
Pradyum Sekar, CEO of CB2 Insights (CSE:CBII), joined Anil Mall at Extraordinary Future 2019 in Vancouver to talk about CB2 Insights as a research and technology company with the aim of mainstreaming medical cannabis, hurdles they faced in the early days of the company, the three primary divisions of the company and their footprint in the US, their recent milestones and experience with going public earlier this year, and where Pradyum would like to see the space go in the next few years.
CB2 Insights (CSE: CBII-OTCQB: CBIIT) CEO Prad Sekar joined Steve Darling on Skype from London with news the company has been selected as an exclusive research technology platform for the UK’s largest medical cannabis Pilot – Project TWENTY21 Sekar told Proactive about that project and how CB2 will be involved.
CB2 Insights (CSE: CBII) CEO Prad Sekar joined Steve Darling from Proactive Investors Vancouver to discuss the company moving into phase 2 of the integration of their program into the Juno platform. Sekar tells Proactive about the results of phase 1 and what they were hearing from physicians using the system.
As a data aggregator within the medical cannabis space, CB2 Insights’ CEO Prad Sekar explains how the company is helping healthcare practitioners by providing more qualified data tools.
With a base of over 80,000 patients across 14 states in the U.S., CB2 Insights Inc. (CBII:CSE) focuses on standardized data collection of clinical trial protocols for medical cannabis industry. CEO Prad Sekar tells how the recent acquisition of Relax Clarity in Colorado could help filling the gap between crowd sourced anecdotal data and the lack of clinical trials within the medical cannabis space. By gathering data and creating objective real-world evidence through proprietary software and clinical service brands, the company hopes to mainstream cannabis into traditional healthcare.
CB2 Insights (CSE:CBII) CEO Prad Sekar joined Steve Darling from Proactive Investors Vancouver to discuss yet another acquisition by the Toronto based company. CB2 buying Colorado-based Relaxed Clarity in a combined stock and cash deal. Sekar telling Proactive why they decided to do this deal and how this sets them up to reach a major revenue milestone.
CB2 Insights (CSE:CBII) CEO Prad Sekar joined Steve Darling from Proactive Investors Vancouver on Skype from Toronto to share news the company has signed an agreement with the British Columbia based Premier Health Group to use the industry’s only medical cannabis-specific Clinical Decision Support tool. This deal gives CB2 access to 4600 physicians and data gathered from over 300 thousand patients.
CB2 Insights (CBII) CEO Prad Sekar joined Steve Darling from proactive Investors on Skype to discuss CB2’s acquisition of MedEval Clinic LLC, a medical cannabis evaluation and education center group with multiple locations in Colorado and Arizona. Sekar discussed why they decided to do the deal and how it fits in the overall strategy at CB2. Sekar also addressed the clinics model and revenue expected to be generated.
CB2 Insights (CSE:CBII) CEO Prad Sekar joined Steve Darling from Proactive Investors Vancouver from Toronto to discuss the company going public. CB2 is now listed on the Canadian Securities Exchange under the ticker CBII. Sekar told Proactive just how big this is for the company and also how they plan on using the 5.7 million dollars they have currently raised .
CB2 Insights (CNSX:CBII) is a predictive analytics, software, and services company operating in the medical cannabis space. CEO Prad Sekar is excited about the company’s launch on the CSE and believes it is another step in achieving the company’s mission of mainstreaming medical cannabis. Sekar sees cannabis becoming a hallmark medication. The company’s technology allows point-of-care data gathering, which will provide the next level of validation for medical cannabis. CB2 Insights operates in 12 states and has 60,000 patient interactions per year. CB2 Insights completed a $5 million non-brokered private placement prior to going public to continue its execution plan and for further acquisitions and consolidation.
In this interview at the recent Cantech Investment Conference 2019 in Toronto, SmallCapPower spoke with Prad Sekar, CEO of CB2 Insights Inc, about the Company’s mission to use data sets and business intelligence to educate the medical community about the use of cannabis, as well as its efficacy and role within a patient’s treatment plan. Watch our short video to find out how CB2 Insights plans to adopt an aggressive acquisition strategy in 2019 as well as list on the Canadian Securities Exchange.
The FDA is changing how real world evidence is used in the pharmaceutical industry so that data collected outside clinical trials has become massively valuable. CB2 Insights' 28 clinics see 65,000 active uniques patients per year and are focused solely on cannabis medicine. CB2 Insights collects controlled data from those clinics using their proprietary technology and is applying predictive analytics to reveal the value in that data. Presenting in this video is Prad Sekar, CEO of CB2 Insights.
Prad Sekar, CEO of CB2 Insights, explains the technology behind his company’s innovations and discusses plans to go public this year.
CB2 Co-Founder and CEO Prad Sekar joined Steve Darling from Proactive Investors in Los Angeles at the LD Micro show to share details of the company that according to them is to deliver the industry’s most comprehensive, data-driven software and services - transforming the way the global cannabis industry evolves through actionable insights. The company is private but has plans to go public in 2019.